Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 5/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409150 | 0.90 | EGLN1 (0.56) | EGLN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL3410878 | 0.86 | EGLN1 (0.63) | EGLN1 | |
| SCHEMBL3409230 | 0.85 | EGLN1 (0.55) | EGLN1PTGER4PDE2A | |
| SCHEMBL3411160 | 0.84 | EGLN1 (0.49) | EGLN1 | |
| SCHEMBL3404173 | 0.80 | EGLN1 (0.43) | EGLN1PTGER4KAT6A | |
| SCHEMBL3435037 | 0.78 | EGLN1 (0.45) | EGLN1 | |
| SCHEMBL4535456 | 0.77 | EGLN1 (0.42) | EGLN1PTGER4CCR1 | |
| SCHEMBL3408985 | 0.76 | MEN1 (0.45) | EGLN1PDE2AKAT6A | |
| SCHEMBL3408688 | 0.75 | EGLN1 (0.48) | EGLN1 | |
| SCHEMBL4537851 | 0.75 | EGLN1 (0.40) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | claimed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | claimed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | claimed |
| EP-2257539-B1 | SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278304-B2 | Substituted 4-hydroxypyrimidine-5-carboxamides | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239876-A1 | Substituted 4-Hydroxypyrimidine-5-Carboxamides | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885HDAC3 458/4885HDAC1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.